Abbott Laboratories to Project Q3 Earnings Growth
Operators should monitor these targets as they reflect broader demand and cost trends within the medical device industry.
Updated on Oct. 21, 2026 in Economic Indicators
Live Poll
Do you believe major corporate earnings reports currently suggest the national economy is strengthening?
Abbott Laboratories projects an adjusted third-quarter earnings per share range of $1.38 to $1.46. The company is set to report its final results for the period on October 21, 2026, ahead of the U.S. market opening.
Why it matters
As a major player in medical technology and diagnostics, Abbott's performance serves as a bellwether for operational costs and demand across the broader healthcare supply chain. Operators look to these figures for signals on market stability and potential shifts in sector-wide pricing power.
Abbott targets an adjusted EPS range of $1.38 to $1.46, comparing against the $1.30 recorded in Q3 2025. This follows a second-quarter 2026 performance that saw $12.59 billion in sales and $1.31 in adjusted diluted earnings per share.
The players
Abbott Laboratories
A global healthcare conglomerate that develops, manufactures, and sells medical devices, diagnostics, and branded generic pharmaceuticals.
The details
Abbott generates guidance by analyzing performance trends against the same period from the prior year, incorporating operational results from its diversified portfolio. The firm uses adjusted diluted earnings to smooth out GAAP volatility, providing a clearer view of core operational margin health. Investors and business partners monitor these quarterly adjustments to gauge the company's ability to navigate current supply chain and demand pressures.
Timeline
Q3 2025: Abbott earned $1.30 adjusted diluted EPS.
Q2 2026: Abbott recorded $1.31 adjusted diluted EPS.
October 21, 2026: Abbott reports third-quarter earnings and holds conference call.
Market Landscape
Abbott’s latest guidance reflects an ongoing effort to maintain consistent growth trajectories within the competitive medical technology sector. The firm seeks to outpace the performance targets set during the 2025 Q3 fiscal earnings report, which serves as the primary benchmark for institutional health.
Operators in the healthcare sector should monitor the upcoming earnings call for insights on pricing and demand trends that could affect procurement costs. Comparing these results against the $12.59 billion in second-quarter sales will help identify current market momentum.
The takeaway
Management’s focus on adjusted EPS continues to be the primary metric for internal performance tracking. Business leaders should watch for the official filing on October 21 to see how these projections align with actual third-quarter operating expenses.
What happens next
Abbott Laboratories will report its official third-quarter results and host a conference call at 9 a.m. ET on October 21, 2026.
Further reading
For broader trends in corporate sector performance, visit the Economic Indicators section.
Live Poll
Do you believe major corporate earnings reports currently suggest the national economy is strengthening?
